AGP Executive Report
Last update: 2 hours agoCancer & Prevention: A new IARC analysis links about 2.3 million cancer cases in 2024 (roughly 1 in 8) to infections, highlighting preventable drivers like HPV, H. pylori, hepatitis B/C, and EBV—a strong case for vaccination, screening, and infection control. Oncology Research: Roche reports evERA results in NEJM: giredestrant plus everolimus significantly improves progression-free survival in ER-positive advanced breast cancer after CDK4/6 inhibitor resistance. Dermatology Trial Update: Upadacitinib continues to show sustained repigmentation in non-segmental vitiligo through week 76 in Viti-Up data. Health Policy & Access: CMS finalizes the GLOBE model for Medicare Part B drugs starting Jan. 1, 2027, with revised savings estimates and potential lower out-of-pocket costs from April 1, 2027 for selected beneficiaries. Public Health Context (France): Student protests in France escalate, with reports of hundreds of school blockades and injuries—raising concerns for continuity of care and education-related wellbeing.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.